Drugmakers go nuclear, continuing push into radiopharmaceuticals

Elie Dolgin • June 10, 2021

With late-stage trial success, venture funding and next-generation alpha emitters on the way, targeted radiotherapy drugs are finally “getting the attention they deserve.”

The clinical success of the first targeted radiopharmaceutical designed to combat a common type of cancer looks poised to help bring the once-fringe treatment modality into the medical mainstream.


Earlier this month, Novartis reported phase 3 data from its VISION trial showing that men with metastatic castration-resistant prostate cancer lived longer when, in addition to standard-of-care treatments, they received the company’s 177Lu-PSMA-617, a small-molecule drug that delivers radiation-emitting lutetium isotopes to cells expressing prostate-specific membrane antigen (PSMA).


Continue reading at Nature Biotechnology.

Yellow rings of DNA amidst white chromosomes
By Elie Dolgin September 11, 2025
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Artificially colored pancreatic islet cells
By Elie Dolgin September 5, 2025
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.